Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
Jiefei Han, Ruofei Yu, Jianchun Duan, Jin Li, Wei Zhao, Guoshuang Feng, Hua Bai, Yuqi Wang, Xue Zhang, Rui Wan, Jiachen Xu, Xin Wang, Yanfang Guan, Xuefeng Xia, Zhuoran Yao, Kailun Fei, David P. Carbone, Zhijie Wang, Jie Wang
Abstract
T cells (shared TCR clones). This index correlated with response and survival outcomes of anti-PD-(L)1 treatment. All the TCR sequences of neoantigen-stimulated T cells were included in the shared TCR clones, indicating that TCR clones involved in TIR index estimation represented tumor-specific T cells. Therefore, the TIR index is a feasible approach for assessing tumor-specific TCR and stratifying patients with NSCLC for anti-PD-(L)1 therapy.
Topics & Concepts
ImmunotherapyT-cell receptorWeightingMedicineClassifier (UML)OncologyImmunologyInternal medicineT cellCancer researchComputer scienceImmune systemArtificial intelligenceRadiologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies